New Zealand markets open in 9 hours 7 minutes

Largest 52-Week Gains

Largest 52-Week Gains

9.19k followers30 symbols Watchlist by Yahoo Finance

Follow this list to discover and track stocks with the greatest 52-week gain. These are stocks whose price has increased the most over the past 52 weeks (percent change). This list is generated daily, the gains are based on today's closing price and limited to the top 30 stocks that meet the criteria.

Curated by Yahoo Finance

Follow this list to discover and track stocks with the greatest 52-week gain. These are stocks whose price has increased the most over the past 52 weeks (percent change). This list is generated daily, the gains are based on today's closing price and limited to the top 30 stocks that meet the criteria.


Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.

Find other winning investment ideas with the Yahoo Finance Screener.

How are these weighted?

The stocks in this watchlist are weighted equally.


WatchlistChange today1-month return1-year returnTotal return
Largest 52-Week Gains----

30 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
TSLATesla, Inc.424.23-25.16-5.60%4:00 pm GMT-479.58M79.41M395.30B
ZMZoom Video Communications, Inc.492.6+24.13+5.15%4:00 pm GMT-416.44M8.89M140.11B
SESea Limited152.12+1.42+0.94%4:00 pm GMT-43.07M4.34M74.19B
DOCUDocuSign, Inc.212.13+7.11+3.47%4:00 pm GMT-45.56M6.24M39.28B
PTONPeloton Interactive, Inc.94.39-0.41-0.43%4:00 pm GMT-443.46M14.75M27.25B
MRNAModerna, Inc.68.72-0.54-0.78%4:00 pm GMT-46.27M19.81M27.12B
GSXGSX Techedu Inc.105.6+0.72+0.69%4:00 pm GMT-41.73M5.10M25.20B
NIONIO Limited19.23+0.42+2.23%4:00 pm GMT-460.20M133.65M23.51B
ZGZillow Group, Inc.98.6+3.79+4.00%4:00 pm GMT-41.32M690.79k22.48B
ZZillow Group, Inc.99.19+3.48+3.64%4:00 pm GMT-43.64M3.69M22.48B
DKNGDraftKings Inc.53.94+2.45+4.76%4:00 pm GMT-419.67M15.98M19.18B
BNTXBioNTech SE67.05+0.93+1.41%4:00 pm GMT-41.56M3.62M15.97B
LVGOLivongo Health, Inc.138.15+7.64+5.85%4:00 pm GMT-42.02M4.63M14.03B
PENNPenn National Gaming, Inc.74.365+4.28+6.11%4:00 pm GMT-49.23M9.99M10.92B
FSLYFastly, Inc.94.31+1.80+1.95%4:00 pm GMT-46.17M11.64M9.92B
CZRCaesars Entertainment, Inc.58.13+3.70+6.80%4:00 pm GMT-44.30M10.45M9.35B
RUNSunrun Inc.62.8+2.60+4.32%4:00 pm GMT-42.48M4.93M7.97B
NVAXNovavax, Inc.111.63+1.48+1.34%4:00 pm GMT-42.40M7.76M6.84B
MNTAMomenta Pharmaceuticals, Inc.52.36-0.01-0.02%4:00 pm GMT-42.70M3.18M6.23B
FVRRFiverr International Ltd.133.07+6.55+5.18%4:00 pm GMT-4862.84k945.67k4.67B
VSLRVivint Solar, Inc.34.53+1.44+4.35%4:00 pm GMT-41.67M3.05M4.33B
CCXIChemoCentryx, Inc.52.83+0.60+1.15%4:00 pm GMT-4869.68k601.64k3.64B
IMVTImmunovant, Inc.35.76+0.84+2.41%4:00 pm GMT-4472.26k534.04k3.47B
PRNBPrincipia Biopharma Inc.100--4:00 pm GMT-4501.35k1.46M3.32B
INOInovio Pharmaceuticals, Inc.16.98-0.71-4.01%4:00 pm GMT-426.89M35.16M2.84B
CWHCamping World Holdings, Inc.31.2+0.21+0.68%4:00 pm GMT-41.89M2.99M2.76B
IGMSIGM Biosciences, Inc.81.8-2.21-2.63%4:00 pm GMT-4345.38k128.29k2.51B
MCRBSeres Therapeutics, Inc.26.49+0.22+0.84%4:00 pm GMT-4478.70k2.97M2.37B
ITCIIntra-Cellular Therapies, Inc.28.41-1.68-5.58%4:00 pm GMT-41.22M1.84M2.24B
MYOVMyovant Sciences Ltd.22.79+0.45+2.01%4:00 pm GMT-4691.55k887.64k2.05B
  • Coronavirus update: Johnson & Johnson vaccine enters phase 3 as Fauci heads to Senate
    Editor's pick
    Yahoo Finance

    Coronavirus update: Johnson & Johnson vaccine enters phase 3 as Fauci heads to Senate

    Johnson & Johnson announced that its coronavirus vaccine candidate had entered the pivotal human trial phase that will enroll up to 60,000 participants worldwide.

  • What Michael Jordan and Bubba Wallace could do for NASCAR
    Editor's pick
    Yahoo Finance

    What Michael Jordan and Bubba Wallace could do for NASCAR

    NASCAR is desperate to attract younger, more diverse fans. Bubba Wallace and Michael Jordan, who will be one of only two Black owners in the Cup Series, are the duo that could make it happen.

  • GlobeNewswire

    Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

    * Prostate cancer and uterine fibroids disproportionately impact Black Americans; racial disparities are exacerbated by inequities in healthcare access and COVID-19 pandemic * Myovant expands ongoing efforts to advance health equity with grant program to award up to $200,000 for innovative projects focused on improving access to healthcare BASEL, Switzerland, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its “Forward for Health Equity” grant program. The program will provide funding to nonprofit healthcare organizations with innovative projects focused on improving healthcare access, with an initial focus on reducing racial disparities in prostate cancer and uterine fibroids in the U.S. Myovant will award as many as four grants of up to $50,000 each, for a total of $200,000. Prostate cancer is the second deadliest cancer in men in the U.S. and has the largest racial disparity of any major cancer, killing Black men twice as often as white men. Uterine fibroids can cause debilitating symptoms such as heavy menstrual bleeding and pain, leading to over 250,000 hysterectomies each year in the U.S., with Black women more likely to undergo more invasive surgical procedures. Studies have also shown that Black men and women have less access to healthcare, and access issues such as lack of insurance coverage have been shown to contribute to the racial disparities in prostate cancer and uterine fibroids.“Myovant is committed to redefining care for women and for men, not only through the development of new medicines but also through initiatives that aim to address the broader societal issues that lead to health inequities,” said Jarrad Aguirre, M.D., head of corporate strategy and advocacy at Myovant Sciences. “We have forged multiple cross-sector partnerships to advocate for a world in which everyone can move forward on their journey with confidence and health, and we are proud to expand our commitment with the launch of the Forward for Health Equity grant program.”Myovant previously launched the Female Forward Together coalition in partnership with Evidation Health, Flo Health, HealthyWomen, and PERIOD, with coalition projects including the development of a digital tool to evaluate menstrual blood loss and the creation of a storytelling initiative to reduce stigma around menstruation. Myovant also recently launched the Forward Momentum coalition in partnership with, Evidation Health, and Movember to improve representation of Black men and women in research studies and to develop digital tools for men with prostate cancer.“Prostate cancer and uterine fibroids have a disproportionate impact on Black men and women, and studies have shown those populations may experience worse outcomes from these diseases due to societal inequities and disparities in healthcare access,” said Reggie Ware, chief executive officer of “These disparities have been exacerbated by the COVID-19 pandemic, making an effort like Myovant’s Forward for Health Equity grant program an urgent priority and an important initiative.”The “Forward for Health Equity” grant program will accept applications through December 31, 2020. Applicants must be U.S.-based nonprofit healthcare organizations. Applicants may not be individual healthcare professionals. Applications will be evaluated based on 1) greatest potential to improve health equity, 2) degree of innovation, and 3) focus on healthcare access. Applications will be reviewed by a committee consisting of Myovant employees and external leaders and advocates.For more information on how to apply, please contact Myovant Sciences  Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Relugolix monotherapy tablet (120 mg) is under regulatory review in the U.S. for men with advanced prostate cancer. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at Follow @Myovant on Twitter and LinkedIn.Investor Contact: Frank Karbe President and Chief Financial Officer Myovant Sciences, Inc. investors@myovant.comMedia Contact: Albert Liao  Director, Corporate Communications Myovant Sciences, Inc.